| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 50 | 2023 | 807 | 6.000 |
Why?
|
| Electronic Nicotine Delivery Systems | 12 | 2025 | 58 | 5.550 |
Why?
|
| Tobacco Smoke Pollution | 16 | 2020 | 88 | 5.030 |
Why?
|
| Tobacco Use Disorder | 10 | 2025 | 88 | 4.290 |
Why?
|
| Smoking Prevention | 7 | 2018 | 33 | 3.180 |
Why?
|
| Vaping | 6 | 2025 | 30 | 2.750 |
Why?
|
| Smoking | 13 | 2024 | 944 | 2.690 |
Why?
|
| Tobacco Products | 8 | 2024 | 70 | 2.550 |
Why?
|
| Smoking Cessation | 9 | 2025 | 193 | 2.250 |
Why?
|
| Anti-Asthmatic Agents | 8 | 2023 | 123 | 2.220 |
Why?
|
| Adrenal Cortex Hormones | 11 | 2023 | 343 | 1.750 |
Why?
|
| Nicotine | 7 | 2025 | 142 | 1.720 |
Why?
|
| Tobacco Industry | 3 | 2018 | 7 | 1.660 |
Why?
|
| Medicaid | 14 | 2023 | 254 | 1.560 |
Why?
|
| Public Policy | 3 | 2016 | 54 | 1.500 |
Why?
|
| Lung | 4 | 2025 | 1571 | 1.370 |
Why?
|
| Palivizumab | 3 | 2018 | 48 | 1.170 |
Why?
|
| Managed Care Programs | 9 | 2023 | 61 | 1.160 |
Why?
|
| Mothers | 3 | 2016 | 373 | 1.090 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2015 | 243 | 1.080 |
Why?
|
| Commerce | 2 | 2016 | 57 | 1.000 |
Why?
|
| Emergency Service, Hospital | 8 | 2024 | 1166 | 0.950 |
Why?
|
| Child Health Services | 2 | 2016 | 88 | 0.920 |
Why?
|
| Respiratory Sounds | 2 | 2018 | 71 | 0.920 |
Why?
|
| Muscular Dystrophies | 1 | 2025 | 54 | 0.900 |
Why?
|
| Adolescent | 51 | 2025 | 20573 | 0.880 |
Why?
|
| Anthropometry | 1 | 2025 | 205 | 0.860 |
Why?
|
| Body Height | 1 | 2025 | 228 | 0.840 |
Why?
|
| Child | 59 | 2025 | 25868 | 0.830 |
Why?
|
| United States | 38 | 2025 | 11722 | 0.810 |
Why?
|
| Lung Injury | 2 | 2021 | 123 | 0.770 |
Why?
|
| Humans | 93 | 2025 | 133373 | 0.750 |
Why?
|
| Parents | 5 | 2017 | 1073 | 0.680 |
Why?
|
| Varenicline | 1 | 2020 | 14 | 0.680 |
Why?
|
| Bupropion | 1 | 2020 | 30 | 0.670 |
Why?
|
| Societies, Medical | 4 | 2025 | 779 | 0.630 |
Why?
|
| Administration, Inhalation | 8 | 2023 | 185 | 0.590 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 1340 | 0.590 |
Why?
|
| Scoliosis | 2 | 2020 | 143 | 0.590 |
Why?
|
| Drug and Narcotic Control | 1 | 2018 | 16 | 0.570 |
Why?
|
| Marketing | 1 | 2017 | 8 | 0.560 |
Why?
|
| Ozone | 2 | 2016 | 20 | 0.550 |
Why?
|
| Analgesics, Non-Narcotic | 3 | 2024 | 81 | 0.540 |
Why?
|
| Medical Overuse | 1 | 2017 | 26 | 0.530 |
Why?
|
| Health Policy | 2 | 2018 | 233 | 0.530 |
Why?
|
| Pamphlets | 1 | 2016 | 24 | 0.520 |
Why?
|
| Drug Prescriptions | 2 | 2023 | 244 | 0.510 |
Why?
|
| Bronchodilator Agents | 5 | 2019 | 153 | 0.500 |
Why?
|
| Analgesics, Opioid | 5 | 2024 | 469 | 0.500 |
Why?
|
| Air Pollutants | 3 | 2016 | 115 | 0.490 |
Why?
|
| Environmental Exposure | 5 | 2020 | 236 | 0.480 |
Why?
|
| Hospitalization | 9 | 2024 | 1921 | 0.460 |
Why?
|
| Child Health | 1 | 2015 | 69 | 0.450 |
Why?
|
| Cohort Effect | 1 | 2014 | 5 | 0.450 |
Why?
|
| Patient Education as Topic | 3 | 2016 | 467 | 0.450 |
Why?
|
| Male | 48 | 2025 | 65592 | 0.440 |
Why?
|
| Female | 48 | 2025 | 71503 | 0.430 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2017 | 233 | 0.430 |
Why?
|
| Respiratory Function Tests | 4 | 2025 | 216 | 0.430 |
Why?
|
| Vital Capacity | 3 | 2025 | 85 | 0.420 |
Why?
|
| Family Relations | 1 | 2014 | 71 | 0.420 |
Why?
|
| Harm Reduction | 3 | 2024 | 12 | 0.410 |
Why?
|
| Respiratory Tract Diseases | 1 | 2013 | 81 | 0.410 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2016 | 377 | 0.380 |
Why?
|
| Child, Preschool | 18 | 2025 | 14873 | 0.380 |
Why?
|
| Cotinine | 2 | 2010 | 24 | 0.370 |
Why?
|
| Fathers | 1 | 2012 | 72 | 0.360 |
Why?
|
| Sex Factors | 2 | 2014 | 1353 | 0.350 |
Why?
|
| Mexican Americans | 4 | 2020 | 169 | 0.340 |
Why?
|
| Cystic Fibrosis | 1 | 2013 | 266 | 0.340 |
Why?
|
| Antiviral Agents | 1 | 2016 | 824 | 0.340 |
Why?
|
| Infant | 11 | 2023 | 13243 | 0.330 |
Why?
|
| Genome-Wide Association Study | 8 | 2019 | 1838 | 0.330 |
Why?
|
| Minority Groups | 4 | 2016 | 251 | 0.320 |
Why?
|
| Albuterol | 4 | 2018 | 52 | 0.310 |
Why?
|
| Young Adult | 19 | 2020 | 9923 | 0.290 |
Why?
|
| Social Class | 4 | 2016 | 207 | 0.290 |
Why?
|
| Genetic Loci | 4 | 2017 | 363 | 0.260 |
Why?
|
| Urban Population | 3 | 2016 | 241 | 0.260 |
Why?
|
| Attitude to Health | 1 | 2008 | 261 | 0.250 |
Why?
|
| Prescriptions | 2 | 2024 | 42 | 0.250 |
Why?
|
| Bronchiolitis | 2 | 2017 | 123 | 0.240 |
Why?
|
| Respiratory Tract Infections | 2 | 2020 | 296 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2018 | 3363 | 0.230 |
Why?
|
| Ulna | 1 | 2025 | 7 | 0.230 |
Why?
|
| Arm | 1 | 2025 | 81 | 0.220 |
Why?
|
| Tibia | 1 | 2025 | 83 | 0.220 |
Why?
|
| Administration, Oral | 2 | 2017 | 719 | 0.220 |
Why?
|
| Cultural Diversity | 1 | 2004 | 71 | 0.210 |
Why?
|
| Quality of Health Care | 2 | 2004 | 423 | 0.210 |
Why?
|
| Retrospective Studies | 9 | 2024 | 17568 | 0.210 |
Why?
|
| Acute Pain | 1 | 2023 | 17 | 0.210 |
Why?
|
| Muscular Dystrophy, Duchenne | 2 | 2020 | 68 | 0.210 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2023 | 772 | 0.200 |
Why?
|
| Abbreviations as Topic | 1 | 2002 | 1 | 0.200 |
Why?
|
| Adult | 13 | 2021 | 31684 | 0.190 |
Why?
|
| Case-Control Studies | 10 | 2019 | 3418 | 0.180 |
Why?
|
| Family | 2 | 2017 | 593 | 0.180 |
Why?
|
| Phenotype | 2 | 2017 | 4577 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2018 | 2855 | 0.180 |
Why?
|
| Spirometry | 1 | 2021 | 75 | 0.170 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2016 | 93 | 0.170 |
Why?
|
| Risk Factors | 15 | 2018 | 10954 | 0.170 |
Why?
|
| Dangerous Behavior | 1 | 2020 | 11 | 0.170 |
Why?
|
| Forced Expiratory Volume | 5 | 2019 | 173 | 0.160 |
Why?
|
| Bronchoscopy | 1 | 2021 | 172 | 0.160 |
Why?
|
| Proteins | 2 | 2017 | 1090 | 0.160 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2020 | 47 | 0.160 |
Why?
|
| Patient Compliance | 1 | 2003 | 477 | 0.160 |
Why?
|
| Primary Health Care | 2 | 2015 | 806 | 0.160 |
Why?
|
| Cohort Studies | 4 | 2023 | 5199 | 0.160 |
Why?
|
| Allergens | 3 | 2016 | 279 | 0.150 |
Why?
|
| Cytidine Deaminase | 1 | 2019 | 32 | 0.150 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2019 | 39 | 0.150 |
Why?
|
| Infant, Newborn | 3 | 2018 | 8632 | 0.150 |
Why?
|
| Odds Ratio | 6 | 2016 | 1254 | 0.150 |
Why?
|
| Spinal Fusion | 1 | 2020 | 115 | 0.150 |
Why?
|
| GTPase-Activating Proteins | 1 | 2019 | 92 | 0.150 |
Why?
|
| Smad2 Protein | 1 | 2018 | 54 | 0.150 |
Why?
|
| Acculturation | 1 | 2019 | 63 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2018 | 62 | 0.150 |
Why?
|
| Health Communication | 1 | 2018 | 31 | 0.150 |
Why?
|
| Telomere Homeostasis | 1 | 2018 | 46 | 0.150 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 158 | 0.140 |
Why?
|
| Pharmacogenomic Variants | 1 | 2018 | 39 | 0.140 |
Why?
|
| Risk | 2 | 2015 | 782 | 0.140 |
Why?
|
| Air Pollution | 2 | 2016 | 75 | 0.140 |
Why?
|
| Flavoring Agents | 1 | 2017 | 4 | 0.140 |
Why?
|
| Pregnancy | 4 | 2015 | 7602 | 0.140 |
Why?
|
| Peer Influence | 1 | 2017 | 3 | 0.140 |
Why?
|
| Texas | 2 | 2017 | 3666 | 0.140 |
Why?
|
| Tobacco Smoking | 1 | 2017 | 20 | 0.140 |
Why?
|
| Child Welfare | 1 | 1998 | 67 | 0.140 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 1 | 2017 | 23 | 0.130 |
Why?
|
| Oxygen | 1 | 2021 | 578 | 0.130 |
Why?
|
| DNA, Intergenic | 1 | 2017 | 19 | 0.130 |
Why?
|
| Skin Pigmentation | 1 | 2017 | 29 | 0.130 |
Why?
|
| Antiporters | 1 | 2017 | 35 | 0.130 |
Why?
|
| Treatment Outcome | 4 | 2021 | 13103 | 0.130 |
Why?
|
| Cigarette Smoking | 1 | 2018 | 80 | 0.130 |
Why?
|
| Genotype | 4 | 2017 | 2720 | 0.130 |
Why?
|
| RNA Splicing Factors | 1 | 2017 | 55 | 0.130 |
Why?
|
| Telomere | 1 | 2018 | 227 | 0.130 |
Why?
|
| Government Regulation | 1 | 2016 | 43 | 0.130 |
Why?
|
| Needs Assessment | 1 | 2018 | 181 | 0.130 |
Why?
|
| Particulate Matter | 2 | 2016 | 80 | 0.130 |
Why?
|
| Cockroaches | 1 | 2016 | 6 | 0.130 |
Why?
|
| Emergency Medical Services | 2 | 2017 | 415 | 0.130 |
Why?
|
| Public Health | 1 | 2019 | 283 | 0.130 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2016 | 52 | 0.130 |
Why?
|
| Gene-Environment Interaction | 2 | 2016 | 130 | 0.130 |
Why?
|
| Drug Utilization | 3 | 2004 | 169 | 0.130 |
Why?
|
| Cost Sharing | 1 | 2016 | 1 | 0.130 |
Why?
|
| Racism | 1 | 2016 | 42 | 0.120 |
Why?
|
| Puerto Rico | 4 | 2019 | 49 | 0.120 |
Why?
|
| Health Personnel | 1 | 2021 | 549 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2023 | 5443 | 0.120 |
Why?
|
| Maternal Age | 1 | 2016 | 141 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 2205 | 0.120 |
Why?
|
| Membrane Transport Proteins | 1 | 2017 | 188 | 0.120 |
Why?
|
| Lung Diseases | 2 | 2018 | 404 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 480 | 0.120 |
Why?
|
| Stress, Psychological | 2 | 2017 | 604 | 0.120 |
Why?
|
| Age Factors | 3 | 2017 | 2956 | 0.110 |
Why?
|
| Algorithms | 1 | 2022 | 1730 | 0.110 |
Why?
|
| Breast Feeding | 1 | 2016 | 240 | 0.110 |
Why?
|
| Prevalence | 3 | 2016 | 2632 | 0.110 |
Why?
|
| Health Expenditures | 1 | 2016 | 117 | 0.110 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 406 | 0.110 |
Why?
|
| Patient Readmission | 1 | 1998 | 430 | 0.110 |
Why?
|
| Ikaros Transcription Factor | 1 | 2014 | 32 | 0.110 |
Why?
|
| Minority Health | 1 | 2013 | 13 | 0.110 |
Why?
|
| Immunoglobulin E | 1 | 2014 | 171 | 0.110 |
Why?
|
| Urban Health | 1 | 2013 | 78 | 0.110 |
Why?
|
| Aged | 4 | 2022 | 21500 | 0.100 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2013 | 17 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 814 | 0.100 |
Why?
|
| Acute Disease | 1 | 2016 | 1184 | 0.100 |
Why?
|
| Emigration and Immigration | 1 | 2013 | 82 | 0.100 |
Why?
|
| Kallikreins | 1 | 2012 | 31 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2019 | 2145 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2012 | 65 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 860 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1714 | 0.100 |
Why?
|
| Infant, Premature | 1 | 2018 | 858 | 0.100 |
Why?
|
| Health Behavior | 2 | 2010 | 400 | 0.100 |
Why?
|
| Pediatrics | 2 | 2017 | 1221 | 0.100 |
Why?
|
| Obesity | 2 | 2015 | 2440 | 0.090 |
Why?
|
| Logistic Models | 5 | 2020 | 1864 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 2092 | 0.090 |
Why?
|
| Gestational Age | 1 | 2016 | 1231 | 0.090 |
Why?
|
| Analgesics | 2 | 2024 | 131 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2015 | 415 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2018 | 3718 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 1 | 2012 | 274 | 0.090 |
Why?
|
| Tracheitis | 1 | 1991 | 14 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2004 | 314 | 0.080 |
Why?
|
| Geriatric Assessment | 1 | 1991 | 191 | 0.080 |
Why?
|
| Cross-Sectional Studies | 5 | 2018 | 3740 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2017 | 1140 | 0.080 |
Why?
|
| Mice | 2 | 2025 | 18936 | 0.080 |
Why?
|
| Social Support | 1 | 1991 | 389 | 0.080 |
Why?
|
| Chromosome Mapping | 3 | 2018 | 1118 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 7141 | 0.070 |
Why?
|
| Counseling | 1 | 2010 | 240 | 0.070 |
Why?
|
| Interviews as Topic | 2 | 2017 | 427 | 0.070 |
Why?
|
| Child Day Care Centers | 1 | 2008 | 27 | 0.070 |
Why?
|
| Mental Health | 1 | 1991 | 378 | 0.070 |
Why?
|
| Confidence Intervals | 2 | 2013 | 280 | 0.070 |
Why?
|
| State Health Plans | 2 | 2004 | 4 | 0.070 |
Why?
|
| Intubation, Intratracheal | 1 | 1991 | 291 | 0.070 |
Why?
|
| Poverty | 3 | 2014 | 438 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2004 | 809 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 3988 | 0.060 |
Why?
|
| Creatinine | 1 | 2008 | 418 | 0.060 |
Why?
|
| Staphylococcal Infections | 1 | 1991 | 573 | 0.060 |
Why?
|
| Animals | 2 | 2025 | 36222 | 0.060 |
Why?
|
| Respiratory Therapy | 1 | 2004 | 21 | 0.060 |
Why?
|
| Poisson Distribution | 1 | 2004 | 50 | 0.060 |
Why?
|
| Family Practice | 1 | 2004 | 91 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2004 | 1463 | 0.050 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2024 | 61 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 910 | 0.050 |
Why?
|
| Data Collection | 1 | 2004 | 396 | 0.050 |
Why?
|
| Caregivers | 1 | 2008 | 594 | 0.050 |
Why?
|
| Mental Recall | 1 | 2002 | 144 | 0.050 |
Why?
|
| Linear Models | 1 | 2023 | 719 | 0.050 |
Why?
|
| Influenza Vaccines | 1 | 2006 | 498 | 0.040 |
Why?
|
| Pain | 1 | 2024 | 470 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2001 | 79 | 0.040 |
Why?
|
| Vaccination | 1 | 2006 | 1019 | 0.040 |
Why?
|
| Middle Aged | 1 | 2020 | 28985 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2002 | 201 | 0.040 |
Why?
|
| Health Status | 1 | 2002 | 414 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2002 | 231 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2020 | 153 | 0.040 |
Why?
|
| Influenza, Human | 1 | 2006 | 700 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2016 | 1713 | 0.040 |
Why?
|
| Communication | 1 | 2003 | 542 | 0.040 |
Why?
|
| Disease Progression | 2 | 2016 | 2246 | 0.040 |
Why?
|
| Educational Status | 2 | 2013 | 294 | 0.030 |
Why?
|
| Louisiana | 1 | 1997 | 137 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2004 | 1070 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 191 | 0.030 |
Why?
|
| Sulfur Dioxide | 1 | 2016 | 5 | 0.030 |
Why?
|
| Geography, Medical | 1 | 2016 | 16 | 0.030 |
Why?
|
| Nitrogen Dioxide | 1 | 2016 | 18 | 0.030 |
Why?
|
| Focus Groups | 1 | 2017 | 214 | 0.030 |
Why?
|
| Public Health Surveillance | 1 | 2016 | 45 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2003 | 906 | 0.030 |
Why?
|
| Leukotriene Antagonists | 1 | 2015 | 18 | 0.030 |
Why?
|
| Morbidity | 1 | 2016 | 255 | 0.030 |
Why?
|
| Education, Nonprofessional | 1 | 2015 | 5 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 795 | 0.030 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2014 | 18 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 300 | 0.030 |
Why?
|
| Immunization | 1 | 2016 | 315 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2014 | 102 | 0.030 |
Why?
|
| San Francisco | 1 | 2013 | 20 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 416 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2016 | 252 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2017 | 658 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2014 | 142 | 0.030 |
Why?
|
| Global Health | 1 | 2018 | 622 | 0.030 |
Why?
|
| Income | 1 | 2013 | 139 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 2013 | 91 | 0.020 |
Why?
|
| Skin Tests | 1 | 2013 | 79 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2004 | 6582 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2013 | 145 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 172 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2014 | 373 | 0.020 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2012 | 87 | 0.020 |
Why?
|
| Institutionalization | 1 | 1991 | 15 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 1697 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 767 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2018 | 1597 | 0.020 |
Why?
|
| Personality Inventory | 1 | 1991 | 176 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 1991 | 107 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 841 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3395 | 0.020 |
Why?
|
| Disease Management | 1 | 2014 | 565 | 0.020 |
Why?
|
| Feedback | 1 | 2010 | 172 | 0.020 |
Why?
|
| Parent-Child Relations | 1 | 2010 | 253 | 0.020 |
Why?
|
| Genome, Human | 1 | 2014 | 1340 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 1991 | 485 | 0.020 |
Why?
|
| Breathing Exercises | 1 | 2004 | 8 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 3105 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2014 | 2720 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2004 | 72 | 0.010 |
Why?
|
| Terminal Care | 1 | 2004 | 121 | 0.010 |
Why?
|
| Time Factors | 1 | 2013 | 6544 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2003 | 295 | 0.010 |
Why?
|
| Sleep Wake Disorders | 1 | 2004 | 188 | 0.010 |
Why?
|
| Vulnerable Populations | 1 | 2003 | 148 | 0.010 |
Why?
|
| Malnutrition | 1 | 2004 | 222 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2004 | 501 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2004 | 519 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2003 | 1236 | 0.010 |
Why?
|